AI English summary of an SEC filing — figures as filed
STERIS STEThe company said its total revenue from continuing operations rose 7% to $1.3 billion for the quarter ended September 30, 2024 2025 ($1.2 billion a year earlier), and constant currency organic revenue also grew 7% in Q2. Net income from continuing operations for the same quarter was $150.2 million, or $1.51 per diluted share.
Key points
AI summaryThe company said its total revenue from continuing operations rose 7% to $1.3 billion for the quarter ended September 30, 2024 2025 ($1.2 billion a year earlier), and constant currency organic revenue also grew 7% in Q2. Net income from continuing operations for the same quarter was $150.2 million, or $1.51 per diluted share.
STERIS said Healthcare revenue for Q2 rose 9% to $944.2 million, and AST revenue rose 9% to $256.7 million. It said AST operating income was $109.9 million, lower than $110.8 million a year earlier, and cited higher labor and energy costs and a loss on a large capital equipment sale.
The company said net cash provided by operating activities for the first half of fiscal 2025 was $554.5 million ($427.2 million a year earlier), and free cash flow was $344.5 million ($284.7 million in the prior-year period). It cited earnings growth and improved working capital as the main drivers of the increase.
The company reiterated its outlook for fiscal 2025 and said it expects adjusted diluted earnings per share of $9.05 to $9.25 (fiscal 2024 $8.20) and free cash flow of approximately $700 million. It expects full-year revenue to increase 6.5 to 7.5%.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 Continuing Operations Revenue $1.3 billion, Continuing Operations Net Income $150.2 million
The company said its total revenue from continuing operations rose 7% to $1.3 billion for the quarter ended September 30, 2024 2025 ($1.2 billion a year earlier), and constant currency organic revenue also grew 7% in Q2. Net income from continuing operations for the same quarter was $150.2 million, or $1.51 per diluted share.
Source · Based on the filing body and exhibits
Segment Revenue and AST Operating Income for Q2
STERIS said Healthcare revenue for Q2 rose 9% to $944.2 million, and AST revenue rose 9% to $256.7 million. It said AST operating income was $109.9 million, lower than $110.8 million a year earlier, and cited higher labor and energy costs and a loss on a large capital equipment sale.
Source · Based on the filing body and exhibits
First-Half Operating Cash Flow $554.5 million, Free Cash Flow $344.5 million
The company said net cash provided by operating activities for the first half of fiscal 2025 was $554.5 million ($427.2 million a year earlier), and free cash flow was $344.5 million ($284.7 million in the prior-year period). It cited earnings growth and improved working capital as the main drivers of the increase.
Source · Based on the filing body and exhibits
Fiscal 2025 Outlook Reiterated
The company reiterated its outlook for fiscal 2025 and said it expects adjusted diluted earnings per share of $9.05 to $9.25 (fiscal 2024 $8.20) and free cash flow of approximately $700 million. It expects full-year revenue to increase 6.5 to 7.5%.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…